AZN logo

AstraZeneca (AZN) Company Overview

Profile

Full Name:

AstraZeneca PLC

Sector:

Healthcare

Country:

United Kingdom

IPO:

May 12, 1993

Indexes:

Description:

AstraZeneca (AZN) is a global biopharmaceutical company that focuses on developing and manufacturing medicines for various diseases, including cancer, cardiovascular, and respiratory conditions. They aim to improve patient health through innovative treatments and research, working with healthcare professionals and organizations worldwide.

Key Details

Price

$72.85

Annual Revenue

$45.81 B(+3.29% YoY)

Annual EPS

$1.91(+80.57% YoY)

Beta

0.21

Events Calendar

Earnings

Next earnings date:

Feb 6, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 6, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Aug 9, 2024
Splits

Next split:

N/A

Recent split:

Jul 27, 2015

Analyst ratings

Recent major analysts updates

Nov 20, 24 UBS
Neutral
Sep 11, 24 Erste Group
Buy
Aug 12, 24 TD Cowen
Buy
May 30, 24 Goldman Sachs
Buy
May 30, 24 Argus Research
Buy
Apr 26, 24 BMO Capital
Outperform
Apr 16, 24 Deutsche Bank
Hold
Feb 12, 24 BMO Capital
Outperform
Feb 8, 24 Deutsche Bank
Hold
Jan 23, 24 Morgan Stanley
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
AZN
accessnewswire.comFebruary 6, 2025

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in finding out about possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=127649&wire=1 or reach out to Joseph E. Levi, Esq.

ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
AZN
globenewswire.comFebruary 6, 2025

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a worldwide law firm focused on investor rights, is reminding buyers of AstraZeneca PLC (NASDAQ: AZN) securities from February 23, 2022, to December 17, 2024, that the deadline to become the lead plaintiff in the securities class action is February 21, 2025.

AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
AZN
accessnewswire.comFebruary 6, 2025

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in finding out about possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=127614&wire=1 or reach out to Joseph E. Levi, Esq.

Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZN
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZN
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZN
AZN
accessnewswire.comFebruary 6, 2025

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=127490&wire=1 or reach out to Joseph E. Levi, Esq.

The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
AZN
prnewswire.comFebruary 6, 2025

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm has an announcement for AstraZeneca PLC (NASDAQ: AZN) shareholders. Those who bought AZN shares during the specified time are invited to reach out to the firm about the chance to be appointed as lead plaintiff.

AstraZeneca: China exposure manageable, says investment bank
AstraZeneca: China exposure manageable, says investment bank
AstraZeneca: China exposure manageable, says investment bank
AZN
proactiveinvestors.co.ukFebruary 6, 2025

AstraZeneca PLC (LSE:AZN) may have to pay a fine of as much as £4.5 million due to a Chinese investigation into the possible illegal import of cancer medications Imfinzi and Imjudo. The Shenzhen City Customs believes there are $0.9 million in unpaid import taxes, and AstraZeneca thinks the fines could be between one and five times that amount.

AstraZeneca receives £6bn boost as earnings beat forecasts
AstraZeneca receives £6bn boost as earnings beat forecasts
AstraZeneca receives £6bn boost as earnings beat forecasts
AZN
proactiveinvestors.co.ukFebruary 6, 2025

AstraZeneca PLC (LSE:AZN) saw its shares rise by 3.5% in early trading, increasing its market value by £6 billion, thanks to impressive annual profits from its cancer, lung, and immunology drugs. In 2024, the company's revenue increased by 21% to $54.1 billion (£43 billion), and its pre-tax profit rose by 38% to $8.7 billion when adjusted for constant currency.

AstraZeneca 2025 sales outlook tops expectations
AstraZeneca 2025 sales outlook tops expectations
AstraZeneca 2025 sales outlook tops expectations
AZN
reuters.comFebruary 6, 2025

On Thursday, AstraZeneca predicted that its sales for 2025 would exceed what analysts had expected, following a strong performance in the fourth quarter. This success was mainly due to high demand for its cancer and heart disease medications.

AstraZeneca PLC Class Action: Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
AstraZeneca PLC Class Action: Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
AstraZeneca PLC Class Action: Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
AZN
accessnewswire.comFebruary 6, 2025

If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in possible recovery under federal securities laws, you can find more details by following the link below: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=127635&wire=1 or reach out to Joseph E. Levi, Esq.

AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AZN
zacks.comFebruary 6, 2025

AstraZeneca has shared mixed results for the fourth quarter. The company's stock rose in pre-market trading after it reassured investors that the effects of the investigations in China are not significant.

FAQ

  • What is the ticker symbol for AstraZeneca?
  • Does AstraZeneca pay dividends?
  • What sector is AstraZeneca in?
  • What industry is AstraZeneca in?
  • What country is AstraZeneca based in?
  • When did AstraZeneca go public?
  • Is AstraZeneca in the S&P 500?
  • Is AstraZeneca in the NASDAQ 100?
  • Is AstraZeneca in the Dow Jones?
  • When was AstraZeneca's last earnings report?
  • When does AstraZeneca report earnings?
  • Should I buy AstraZeneca stock now?

What is the ticker symbol for AstraZeneca?

The ticker symbol for AstraZeneca is NASDAQ:AZN

Does AstraZeneca pay dividends?

Yes, AstraZeneca pays dividends. The last payment was $0.50, with an ex-dividend date on August 9, 2024

What sector is AstraZeneca in?

AstraZeneca is in the Healthcare sector

What industry is AstraZeneca in?

AstraZeneca is in the Drug Manufacturers - General industry

What country is AstraZeneca based in?

AstraZeneca is headquartered in United Kingdom

When did AstraZeneca go public?

AstraZeneca's initial public offering (IPO) was on May 12, 1993

Is AstraZeneca in the S&P 500?

No, AstraZeneca is not included in the S&P 500 index

Is AstraZeneca in the NASDAQ 100?

Yes, AstraZeneca is included in the NASDAQ 100 index

Is AstraZeneca in the Dow Jones?

No, AstraZeneca is not included in the Dow Jones index

When was AstraZeneca's last earnings report?

AstraZeneca's most recent earnings report was on Nov 12, 2024

When does AstraZeneca report earnings?

The next expected earnings date for AstraZeneca is Feb 6, 2025

Should I buy AstraZeneca stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions